Auris Health, Ethicon ’ s NeuWave ink robot-assisted bronchoscope ablation dev deal

Auris Health, previously known as Auris Surgical Robotics, said today it inked a cooperative development and commercialization deal with Johnson &Johnson (NYSE:JNJ) division Ethicon’s NeuWave Medical subsidiary looking to develop systems for the robotically-assisted bronchoscopic ablation of lung lesions. Through the agreement, both companies will help develop an integrated system for robotic control, navigation and application of bronchoscope-delivered microwave ablation. The bronchoscope in development will be equipped with a small camera and accessory channel to allow tools to enter the lungs through the mouth, Auris said. “For those treating people with suspicious nodules in the lung, the holy grail is to one day be able to detect and treat the disease in a single procedure. When this option becomes a reality, we may see many patients seek early screening and minimally invasive treatment,” Dr. Kazuhiro Yasufuku of the University of Toronto said in a prepared release. The development deal also covers tech optimization and procedure development, Redwood City, Calif.-based Auris said. “From the beginning, our vision has been to create a platform capable of enabling advanced diagnosis and therapy for a spectrum of disease, using the least-invasive approach. We are honored to have Ethicon as a partner. Through this collaboration, we believe we are taking a significant first step together toward making the goal of diagnosing and treating lung ca...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Endoscopic / Arthroscopic Respiratory Robotics aurishealth Ethicon johnsonandjohnson NeuWave Medical Inc. Source Type: news

Related Links:

This study sought to develop a simple and sensitive competitive enzyme-linked immunosorbent assay (ELISA) to quantify afatinib in plasma for routine pharmacokinetic applications. An anti-afatinib antibody was obtained using (S)-N-4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)-quinazoline-4,6-diamine (CTQD), which has the same substructure as afatinib, as a hapten. Enzyme labeling of afatinib with horseradish peroxidase was similarly performed using CTQD. A simple competitive ELISA for afatinib was developed based on the principle of direct competition between afatinib and the enzyme marker for the anti-afatinib an...
Source: Journal of Pharmaceutical Analysis - Category: Drugs & Pharmacology Source Type: research
Could it make surgery smarter? Related items fromOnMedica Cancer patients using complementary meds die sooner NICE updates lung cancer guidance Sentinel node biopsy first to check spread of oral cancer Surgeons forced to lie about their hours Cancer strategies failed to improve one-year survival
Source: OnMedica Blogs - Category: General Medicine Source Type: blogs
Condition:   Local Advanced Non-small Cell Lung Cancer Interventions:   Dietary Supplement: ONS from the start of radiotherapy;   Dietary Supplement: ONS from the time of grade 2 radiation esophagitis;   Dietary Supplement: Energy goal-based ONS;   Dietary Supplement: Prealbumin goal-based ONS;   Radiation: Thoracic radiotherapy;   Drug: Weekly DP che motherapy concurrent with thoracic radiotherapy Sponsor:   Sun Yat-sen University Recruiting
Source: - Category: Research Source Type: clinical trials
Authors: Xu J, Ong HX, Traini D, Byrom M, Williamson J, Young PM Abstract Airway stents are commonly used in the management of patients suffering from central airway obstruction (CAO). CAO may occur directly from airway strictures, obstructing airway cancers, airway fistulas or tracheobronchomalacia, resulting from weakening and dynamic collapse of the airway wall. Current airway stents are constructed from biocompatible medical-grade silicone or from a nickel-titanium (nitinol) alloy with fixed geometry. The stents are inserted via the mouth during a bronchoscopic procedure. Existing stents have many shortcomings ...
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Conclusion Ammonium sulfate gradient method can be successfully applied to prepare afatinib liposomes that performed higher encapsulation efficiency and smaller particle size. The UV spectrophotometry employed to determine the liposome encapsulation efficiency was easy operation and with high accuracy. 
 DOI: 10.3779/j.issn.1009-3419.2018.09.02
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsAll results suggest that AMF can be a potential PARP-1 inhibitor and a candidate adjuvant agent to boost the anticancer effect of CBP in NSCLC.Graphical abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
Authors: Lesueur P, Martel-Laffay I, Escande A, Kissel M, Locher C, Gervais R, Schott R, Vergnenegre A, Chouaid C Abstract INTRODUCTION: Cisplatin-based chemotherapy administered concomitantly to thoracic radiotherapy is the treatment recommended by the European guidelines for fit patients with unresectable stage III non-small cell lung cancer (NSCLC). Cisplatin may be combined with etoposide, vinorelbine or other vinca alkaloids, which act also as radiation sensitizers. Initially administered intravenously, vinorelbine is also available as oral formulation and is the only orally available microtubule-targeting age...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
AbstractThree new dihydrobenzofuran neolignans, myticaganal A –C (1–3), along with five known compounds (4–8), were isolated from the seeds ofMyristica fragrans. Their structures were elucidated by extensive spectroscopic analysis. In vitro cytotoxic activities of the isolated compounds against three human cancer cell lines (KB, oral cavity; MCF-7, breast cancer; and NCI-H187, small cell lung cancer) were evaluated. Neolignan3 showed significant cytotoxicity against KB and NCI-H187 cell lines with IC50 values of 5.9 and 6.3  μM, respectively.
Source: Journal of Natural Medicines - Category: Drugs & Pharmacology Source Type: research
Cancer Medicine, EarlyView.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: Exact incidence of T790M mutations after progression on TKI s in Asian population is not exactly known and requires large data, as incidence may be different than reported in the Western population. Rebiopsy and ddPCR help to determine the most common type of resistance after progression on TKI, for which effective targeted therapy is available.
Source: Lung India - Category: Respiratory Medicine Authors: Source Type: research
More News: Arthroscopy | Bronchoscopy | Cancer | Cancer & Oncology | Endoscopy | Lung Cancer | Medical Ethics | Oral Cancer | Respiratory Medicine